There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kymera Therapeutics (KYMR – Research Report) and Allogene Therapeutics (ALLO – Research Report) with bullish sentiments.
Kymera Therapeutics (KYMR)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Kymera Therapeutics, with a price target of $30.00. The company’s shares closed last Thursday at $27.22.
According to TipRanks.com, Fein is a 5-star analyst with an average return of
Currently, the analyst consensus on Kymera Therapeutics is a Moderate Buy with an average price target of $36.00, implying a 56.0% upside from current levels. In a report released yesterday, J.P. Morgan also upgraded the stock to Buy with a $34.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Allogene Therapeutics (ALLO)
In a report released today, Sami Corwin from William Blair maintained a Buy rating on Allogene Therapeutics. The company’s shares closed last Thursday at $3.39.
According to TipRanks.com, Corwin is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Allogene Therapeutics with a $12.14 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on KYMR:
- Kymera Therapeutics Announces Pricing of $275 Million Public Offering
- Kymera Therapeutics Announces Proposed Public Offering
- R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases
- Analyst Downgrade Sends Kymera Therapeutics (NASDAQ:KYMR) Plunging
- The biopharmaceuticals stocks to own in 2024, according to BofA
